SCHEMBL12855014

SCHEMBL12855014

CCc1cccc(OCOC)c1CO

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTPN1 P18031 1/20 0.41
GABRA1 P14867 2/20 0.38
GABRB2 P47870 2/20 0.38
L3MBTL1 Q9Y468 3/20 0.38
MAPT P10636 2/20 0.38
NPSR1 Q6W5P4 1/20 0.38
EGFR P00533 1/20 0.37
HPGD P15428 1/20 0.36
ATM Q13315 1/20 0.36
CHEK1 O14757 1/20 0.35
AURKA O14965 1/20 0.35
DAPK3 O43293 1/20 0.35
JAK2 O60674 1/20 0.35
ABL1 P00519 1/20 0.35
NTRK1 P04629 1/20 0.35
FYN P06241 1/20 0.35
CSF1R P07333 1/20 0.35
RET P07949 1/20 0.35
IGF1R P08069 1/20 0.35
MET P08581 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6283334 0.90 PTPN1 (0.40) PTPN1GABRA1EGFRCHEK1AURKA
SCHEMBL10434845 0.87 PTPN1 (0.38) PTPN1GABRA1GABRB2L3MBTL1MAPT
SCHEMBL9901198 0.79 PTPN1 (0.37) PTPN1L3MBTL1EGFRCHEK1AURKA
SCHEMBL27655777 0.78 L3MBTL1 (0.58) PTPN1L3MBTL1MAPTNPSR1EGFR
SCHEMBL13791138 0.77 PTPN1 (0.44) PTPN1GABRA1GABRB2L3MBTL1MAPT
SCHEMBL2048597 0.77 EGFR (0.41) PTPN1L3MBTL1MAPTNPSR1EGFR
SCHEMBL27655748 0.77 L3MBTL1 (0.38) PTPN1L3MBTL1MAPTNPSR1HPGD
SCHEMBL9901394 0.76 PTPN1 (0.38) PTPN1EGFRALOX5PTGS2KDM4E
SCHEMBL8973829 0.76 L3MBTL1 (0.40) PTPN1GABRA1GABRB2L3MBTL1MAPT
SCHEMBL30566658 0.76 PTPN1 (0.46) PTPN1L3MBTL1EGFRCHEK1AURKA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2195322-B1 IMIDAZO[1,2-A]PYRIMIDINE DERIVATIVES FOR TREATING DISEASES SUCH AS DIABETES MERCK PATENT GMBH (DE) 2014-08-06 EP disclosed
US-8278312-B2 Imidazo 1,2-a pyrimidine derivatives for the treatment of diseases such as diabetes MERCK Patent Gesellschaft mit beschränkter Haftung (DE) 2012-10-02 US disclosed
US-8278312-B2 Imidazo 1,2-a pyrimidine derivatives for the treatment of diseases such as diabetes MERCK Patent Gesellschaft mit beschränkter Haftung (DE) 2012-10-02 US disclosed
US-20100249151-A1 IMIDAZO 1, 2-A PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF DISEASES SUCH AS DIABETES Merck Patent Gesellschaft Beschrankter Haftung (DE) 2010-09-30 US disclosed
US-20100249151-A1 IMIDAZO 1, 2-A PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF DISEASES SUCH AS DIABETES Merck Patent Gesellschaft Beschrankter Haftung (DE) 2010-09-30 US disclosed
WO-2009049731-A1 IMIDAZO[1,2-A]PYRIMIDINE DERIVATIVES FOR TREATING DISEASES SUCH AS DIABETES MERCK PATENT GMBH (DE) 2009-04-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100249151-A1 IMIDAZO 1, 2-A PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF DISEASES SUCH AS DIABETES TYMS, CCNT1, INSR PTPN1 872/4885GABRA1 3159/4885GABRB2 3812/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.